Why is the comparison with Medicare for YUFLYMA(CF) 40 MG/0.4 ML AUTOINJECTOR labelled estimated?

Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Yuflyma(Cf) Autoinjector / Adalimumab-Aaty: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on brand name.

Why does this page start at 1 unit (EA)?

NADAC prices this product per EA, and the FDA NDC Directory lists its 2 NDCs as dosage form “KIT” with no route. Only a tablet, capsule, lozenge or troche with route “ORAL”, or a tablet or film with route “SUBLINGUAL” or “BUCCAL”, starts at 30, and none of these is one. NADAC’s EA for it may be the whole kit or one item in it, and the files do not say which. So the card starts at 1 unit (EA) rather than guess how many make up a fill; change it to match your prescription.

YUFLYMA(CF) 40 MG/0.4 ML AUTOINJECTOR

FDA nonproprietary name: adalimumab-aaty

For 1 unit (EA)

Pharmacies pay

$896.84 – $912.21 filed

1 × $896.83875 to $912.214 per EA (the 2 NDCs differ)

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$3,487.77 filed

1 × $3,487.76811 per EA, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

The spread

3.8× – 3.9× estimated

Medicare paid between 3.8× and 3.9× what pharmacies pay, depending on the NDC.

Part D averages every strength and form sold under “Yuflyma(Cf) Autoinjector” / “Adalimumab-Aaty” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$1,036.37 – $1,054.04 estimated

NADAC for the pack + 15% + $5.00 fee per fill

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

YUFLYMA(CF) 40 MG/0.4 ML AUTOINJECTOR is how the CMS NADAC file names this product. The FDA NDC Directory lists it as adalimumab-aaty, under the trade name “Yuflyma”.

FDA gives its dosage form as kit.

The labeler, the company named on the label, is CELLTRION USA, Inc.

FDA lists no Established Pharmacologic Class for it.

The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes).

NADAC classes it in its brand rate-setting class B-BIO, and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $896.84 – $912.21 for 1 unit (EA), depending on the NDC ($896.83875 to $912.214 per EA), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

What NADAC measures · NADAC explanation codes

All 2 NDCs

72606-0030-09 · CELLTRION USA, Inc. · $912.214 per EA · eff. 2026-09-23 filed
72606-0030-10 · CELLTRION USA, Inc. · $896.83875 per EA · eff. 2026-09-23 filed

Other strengths, forms and brands

1 other product in the NADAC file shares the FDA nonproprietary name adalimumab-aaty with YUFLYMA(CF) 40 MG/0.4 ML AUTOINJECTOR.

Product	Pharmacies pay per unit	Medicare per unit
ADALIMUMAB-AATY(CF) 40 MG/0.4 ML AUTOINJECTOR generic · kit	$490.03675 to $501.46018 per EA filed eff. 2026-09-23	We don’t know yet
YUFLYMA(CF) 40 MG/0.4 ML AUTOINJECTOR this page brand · kit	$896.83875 to $912.214 per EA filed eff. 2026-09-23	$3,487.76811 per EA filed Part D 2024 average

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

What Medicare paid

Medicare Part D paid $3,487.77 for 1 unit (EA), at an average of $3,487.76811 per EA in 2024 (2024-01-01 to 2024-12-31) for “Yuflyma(Cf) Autoinjector” and “Adalimumab-Aaty”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 739 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

What is your cash price for 1 unit (EA)? Is it lower than what I would pay through my insurance?
Which NDC (the 11-digit number on the package) is this? Pharmacies pay $896.83875 to $912.214 per EA for this product, depending on the NDC.
If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.

Questions

Why is the comparison with Medicare for YUFLYMA(CF) 40 MG/0.4 ML AUTOINJECTOR labelled estimated?: Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Yuflyma(Cf) Autoinjector / Adalimumab-Aaty: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on brand name.
Why does this page start at 1 unit (EA)?: NADAC prices this product per EA, and the FDA NDC Directory lists its 2 NDCs as dosage form “KIT” with no route. Only a tablet, capsule, lozenge or troche with route “ORAL”, or a tablet or film with route “SUBLINGUAL” or “BUCCAL”, starts at 30, and none of these is one. NADAC’s EA for it may be the whole kit or one item in it, and the files do not say which. So the card starts at 1 unit (EA) rather than guess how many make up a fill; change it to match your prescription.